Prof. Yingyi Wang 王颖轶
Chief Physician, Professor
Department of Medical Oncology, Peking Union Medical College Hospital, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Precision diagnosis and personalized treatment for early, middle, and late-stage lung cancer, including targeted therapy, immunotherapy, and chemotherapy. Expertise in screening lung nodules, differentiating benign from malignant cases, and monitoring immune function.
Dr. Wang focuses on precision diagnosis and personalized treatment for lung cancer and differentiating lung nodules. Research examines immune function monitoring and cancer progression. Dr. Wang developed a precision diagnosis and treatment system at Peking Union Medical College Hospital over eight years and engages in medical science popularization.
Professional roles
- Vice Chair, Immunotherapy Adverse Event Management Professional Committee, Beijing Cancer Prevention and Treatment Society
- Vice Chair, Lung Cancer Diagnosis and Treatment Expert Committee, Beijing Health Promotion Association
- Standing Committee Member, Health Science Popularization Working Committee, Beijing Integrative Medicine Society
- Editorial Board Member, Chinese Journal of Clinical Nutrition
Name order: in Chinese the family name comes first (Wang Yingyi). Papers usually list the name as Yingyi Wang or Wang Y.
Selected publications
60 papers on PubMed matched by name and affiliation; 20 as first or senior author since 2016. Most recent first- or senior-author papers:
- Mod Pathol, 2026 (senior author): Genomic and Transcriptomic Characterization of Angiosarcomas: Focus on Cardiac Origin. PubMed 42874741
- Ther Adv Med Oncol, 2026 (senior author): Adjuvant FOLFIRINOX versus S-1 monotherapy for resected PDAC: retrospective real-world data. PubMed 42719505
- MedComm (2020), 2026 (senior author): Dynamics of Circulating Tumor DNA (ctDNA) Predict Treatment Efficacy and Prognosis in Patients With Advanced Pancreatic Cancer: A Prospective Large-Cohort Study. PubMed 42345005
- Lung Cancer, 2025 (senior author): MRD status combined with TNM staging optimizes postoperative prognostic stratification in non-small cell lung cancer: a meta-analysis and systematic review. PubMed 40580589
- Discov Oncol, 2025 (senior author): Thyroid hormone receptor interacting protein 13 is associated with prognosis and immunotherapy efficacy in human cancers: a pan-cancer analysis. PubMed 40253660
- Lung Cancer, 2023 (senior author): Alectinib relieves ischemic strokes caused by left atrial metastasis in a NSCLC patient with a novel SLC34A2-ALK (exon 1: exon 15) fusion. PubMed 37542770
- Front Oncol, 2023 (senior author): Prognostic and predictive significance of circulating biomarkers in patients with advanced upper gastrointestinal cancer undergoing systemic chemotherapy. PubMed 37346066
- Lung Cancer, 2023 (senior author): Genomic and transcriptomic insights into the precision treatment of pulmonary enteric adenocarcinoma. PubMed 37003209
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion